Clovis Oncology Announces Availability and Reimbursement for Rubraca (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Nachrichtenquelle: Business Wire (engl.)
03.02.2020, 10:00  |  739   |   |   

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in France. Rubraca (rucaparib) is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.2 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.2

“This is excellent news as this represents an important new option for patients with relapsed ovarian cancer who have responded to platinum-based chemotherapy,” said a spokesperson for IMAGYN, the only French network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “For too long, ovarian cancer treatment options beyond chemotherapy, surgery and anti-angiogenic therapy have been limited, and today’s announcement means that eligible women with ovarian cancer have more choice in their treatment than ever before.”

Approximately 5,000 women are diagnosed with ovarian cancer in France every year, which equates to roughly 14 every day.3 Ovarian cancer is the eighth most common cancer in women and the fourth most fatal cancer in France.4 In addition, approximately 25 percent of ovarian cancer patients harbor a BRCA1/2 mutation in the tumor, correlating to improved outcomes to platinum and PARP inhibitors therapy.5,6 The majority of women diagnosed with ovarian cancer are BRCA wild-type; these patients typically have a worse prognosis.5,6 Of those treated with surgery and first line chemotherapy, approximately 70 percent of patients will relapse within the first three years.7

“The availability of rucaparib is good news, as ovarian cancer is a disease often diagnosed at an advanced stage and many women may have a poor prognosis,” said Professor Isabelle Ray-Coquard, President of the GINECO Group, which specializes in clinical and translational research in the field of women's cancers, and sets up and coordinates clinical trials in France and abroad. “Patients with relapsed ovarian cancer may have many debilitating symptoms, and it is important that new treatments such as rucaparib are made available to the eligible patients that may benefit from them.”

Seite 1 von 6
Clovis Oncology Aktie jetzt für 4€ handeln - auf

Diesen Artikel teilen

Diskussion: CLOVIS Oncology

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten